Cargando…

COVID-19, myocardial edema and dexamethasone

Severe acute respiratory syndrome corona virus 2(SARS-CoV-2), the cause of coronavirus disease- 2019 (COVID-19) after emerging in china in late 2019 is spreading rapidly across the world. The most common cause of death in patient with COVID-19 is the rapid progression of acute respiratory distress s...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafiee, Moezedin Javad, Babaki Fard, Faranak, Friedrich, Matthias G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834646/
https://www.ncbi.nlm.nih.gov/pubmed/33035967
http://dx.doi.org/10.1016/j.mehy.2020.110307
_version_ 1783642330829422592
author Rafiee, Moezedin Javad
Babaki Fard, Faranak
Friedrich, Matthias G.
author_facet Rafiee, Moezedin Javad
Babaki Fard, Faranak
Friedrich, Matthias G.
author_sort Rafiee, Moezedin Javad
collection PubMed
description Severe acute respiratory syndrome corona virus 2(SARS-CoV-2), the cause of coronavirus disease- 2019 (COVID-19) after emerging in china in late 2019 is spreading rapidly across the world. The most common cause of death in patient with COVID-19 is the rapid progression of acute respiratory distress syndrome (ARDS) shortly after the beginning of dyspnea and hypoxemia. Patients with severe COVID-19 may also develop acute cardiac, kidney and liver injury that are associated with poor prognosis and can lead to high mortality rate. Numerous randomized trials are ongoing to find an effective, safe and widely available treatment. Remdisivir is the only FDA -approved antiviral agent for treatment of severe COVID-19. Glucocorticoids (GCs) have been used for treatment of cytokine storm syndrome and respiratory failure in hospitalized patient with severe covid-19. One of the therapeutic effects of GCs is stability of vascular endothelial barrier and decreasing tissue edema. In our opinion, the decreasing vascular permeability effect of glucocorticoids in the injured myocardium might has an important additional factor in reducing mortality in severe, hospitalized COVID-19 patients.
format Online
Article
Text
id pubmed-7834646
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-78346462021-01-26 COVID-19, myocardial edema and dexamethasone Rafiee, Moezedin Javad Babaki Fard, Faranak Friedrich, Matthias G. Med Hypotheses Article Severe acute respiratory syndrome corona virus 2(SARS-CoV-2), the cause of coronavirus disease- 2019 (COVID-19) after emerging in china in late 2019 is spreading rapidly across the world. The most common cause of death in patient with COVID-19 is the rapid progression of acute respiratory distress syndrome (ARDS) shortly after the beginning of dyspnea and hypoxemia. Patients with severe COVID-19 may also develop acute cardiac, kidney and liver injury that are associated with poor prognosis and can lead to high mortality rate. Numerous randomized trials are ongoing to find an effective, safe and widely available treatment. Remdisivir is the only FDA -approved antiviral agent for treatment of severe COVID-19. Glucocorticoids (GCs) have been used for treatment of cytokine storm syndrome and respiratory failure in hospitalized patient with severe covid-19. One of the therapeutic effects of GCs is stability of vascular endothelial barrier and decreasing tissue edema. In our opinion, the decreasing vascular permeability effect of glucocorticoids in the injured myocardium might has an important additional factor in reducing mortality in severe, hospitalized COVID-19 patients. Published by Elsevier Ltd. 2020-12 2020-09-28 /pmc/articles/PMC7834646/ /pubmed/33035967 http://dx.doi.org/10.1016/j.mehy.2020.110307 Text en Crown Copyright © 2020 Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Rafiee, Moezedin Javad
Babaki Fard, Faranak
Friedrich, Matthias G.
COVID-19, myocardial edema and dexamethasone
title COVID-19, myocardial edema and dexamethasone
title_full COVID-19, myocardial edema and dexamethasone
title_fullStr COVID-19, myocardial edema and dexamethasone
title_full_unstemmed COVID-19, myocardial edema and dexamethasone
title_short COVID-19, myocardial edema and dexamethasone
title_sort covid-19, myocardial edema and dexamethasone
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834646/
https://www.ncbi.nlm.nih.gov/pubmed/33035967
http://dx.doi.org/10.1016/j.mehy.2020.110307
work_keys_str_mv AT rafieemoezedinjavad covid19myocardialedemaanddexamethasone
AT babakifardfaranak covid19myocardialedemaanddexamethasone
AT friedrichmatthiasg covid19myocardialedemaanddexamethasone